The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.


Updates from The Motley Fool

Latest updates on Biogen from Fool.com.  The Fool has written over 600 articles on Biogen.
What's Biogen's Big Risk?

The company's facing an increasingly competitive market for its best-selling drugs.

What's Worrying Me About Biogen

Biogen could struggle to maintain its market-leading position in multiple sclerosis over the next...



Stock Performance

View Interactive BIIB Charts
Sponsored by

Key Data Points

Primary metrics and data points about Biogen.
Current Price: $342.41
Prev Close: $344.44
Open: $347.57
Bid: $338.50
Ask: $349.90
Day's Range: $341.82 - $347.57
52wk Range: $244.28 - $348.84
Volume: 1,208,163
Avg Vol 1,119,095
Market Cap: $72B
P/E (ttm): 21.12
EPS (ttm): $16.31
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Biogen.
CAPS Rating 4 out of 5
 
1003 Outperform
70 Underperform
CAPS All Stars
 
248 Outperform
10 Underperform

How do you think Biogen will perform against the market?



You pick for Biogen is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Michel Vounatsos, CEO

47% Approve

Based on 45 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Biogen.

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers